Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: Characterization, immunogenicity, and stability assessment

Journal of Pharmaceutical Sciences

Volumn 103, Issue 11, 2014, Pages 3448-3456

  Barhate, Ganesh ^a,b   Gautam, Manish ^b   Gairola, Sunil ^b   Jadhav, Suresh ^b   Pokharkar, Varsha ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b Serum Institute of India Ltd   (India)

Author keywords

Asparagus racemosus; Chitosan; Gold nanoparticle; Immunology; In vitro in vivo correlations (IVIVC); Physical characterization; Transmucosal drug delivery; Vaccine adjuvant; Vaccine delivery systems

Indexed keywords

ASPARAGUS RACEMOSUS EXTRACT; CHITOSAN; GOLD NANOPARTICLE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; TETANUS TOXOID; BACTERIUM ANTIBODY; DRUG CARRIER; GOLD; IMMUNOLOGICAL ADJUVANT; METAL NANOPARTICLE; PLANT EXTRACT; SAPONIN;

ANIMAL EXPERIMENT; ARTICLE; CIRCULAR DICHROISM; DISPERSION; DRUG ANTIGENICITY; DRUG DELIVERY SYSTEM; ELECTRON DIFFRACTION; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; HEMOLYSIS; HYDROLYSIS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPOTENTIATION; INFRARED SPECTROSCOPY; INTESTINE; MOUSE; NONHUMAN; PARTICLE SIZE; STOMACH; ZETA POTENTIAL; ANIMAL; ASPARAGUS; BLOOD; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; DRUG STORAGE; IMMUNOLOGY; MEDICINAL CHEMISTRY; MOUTH MUCOSA; MUCOSAL IMMUNITY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; SPECTROFLUOROMETRY; TIME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ASPARAGUS PLANT; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CIRCULAR DICHROISM; DRUG CARRIERS; DRUG STABILITY; DRUG STORAGE; GOLD; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; METAL NANOPARTICLES; MICE; MOUTH MUCOSA; PLANT EXTRACTS; SAPONINS; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL; TETANUS TOXOID; TIME FACTORS;

EID: 84915749324     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24161     Document Type: Article

References (22)

1. Shahiwala A, Vyas TK, Amiji MM. 2007. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 1:1-9.
2. Sharma S, Mukkur TKS, Benson HAE, Chen Y. 2009. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 98:812-843.
3. Borges O, Borchard G, Verhoef JC, de Sousa A, Junginger HE. 2005. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 299:155-166.
4. Chen MC, Mi FL, Liao ZX, Hsiao CW, Sonaje K, Chung MF, Hsu LW, Sung HW. 2013. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 65:865-879.
5. Suna HX, Xiea Y, Ye YP. 2009. ISCOMs and ISCOMATRIX™. Vaccine 27:4388-4401.
6. Gautam M, Diwanay S, Gairola S, Shinde Y, Patki P, Patwardhan B. 2004. Immunoadjuvant potential of Asparagus racemosus aqueous extract in experimental system. J Ethnopharmac 91:251-255.
7. Gautam M, Saha S, Kaul SB, Mishra S, Patil D, Satti NK, Suri KA, Gairola S, Suresh K, Jadhav S, Qazi GN, Patwardhan B. 2009. Immunomodulatory activity of Asparagus racemosus on systemic Th1/Th2 immunity: Implications for immunoadjuvant potential. J Ethnopharmac 121:241-247.
8. Patil D, Gautam M, Gairola S, Jadhav S, Patwardhan B. 2014. HPLC-tandem mass spectrometric studies on steroidal saponins: A case example of quantitative estimation of shatavarin IV from dietary supplements containing Asparagus racemosus. J AOAC Int 97:1-7.
9. Oliveira-Freitas E, Casas CP, Borja-Cabrera GP, Santos FN, Nico D, Souza LOP, Tinoco LW, Da Silva BP, Palatnik M, Parente JP, Palatnik-de-Sousa CB. 2006. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 24:3909-3920.
10. Bhumkar DR, Joshi HM, Sastry M, Pokharkar VB. 2007. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res 24:1415-1426.
11. Matsuda K, Chaudhari AA, Lee JH. 2011. Evaluation of safety and protection efficacy on cpxR and ion deleted mutant of Salmonella Gallinarum as a live vaccine candidate for fowl typhoid. Vaccine 29:668-674.
12. O'Neal CM, Crawford SE, Estes MK, Conner ME. 1997. Rotavirus VLPs administered mucosally induce protective immunity. J Virol 71:8707-8717.
13. Barhate G, Gautam M, Gairola S, Jadhav S, Pokharkar V. 2013. Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: Stability and immunoefficiency studies. Int J Pharm 441:636-642.
14. Barhate GA, Gaikwad SM, Jadhav SS, Pokharkar VB. 2014. Structure function attributes of gold nanoparticle vaccine association: Effect of particle size and association temperature. Int J Pharm 471:439-448.
15. Kumar CG, Mamidyala SK, Sreedhar B, Reddy BV. 2011. Synthesis and characterization of gold glyconanoparticles functionalized with sugars of sweet Sorghum syrup. Biotechnol Prog 27:1455-1463.
16. Johansen P, Merkle HP, Gander B. 1998. Physico-chemical and antigenic properties of tetanus and diphtheria toxoids and steps towards improved stability. Biochim Biophys Acta 1425:425-436.
17. Zhu J, Li JJ, Wang AQ, Chen Y, Zhao JW. 2010. Fluorescence quenching of alpha-fetoprotein by gold nanoparticles: Effect of dielectric shell on non-radiative decay. Nanoscale Res Lett 5:1496-1501.
18. Carbonaro M, Nucara A. 2010. Secondary structure of food proteins by Fourier transform spectroscopy in the mid-infrared region. Amino Acids 38:679-690.
19. US FDA: Guide to inspections oral solutions and suspensions. 2012. Accessed July 1, 2012, at: http://www.fda.gov/iceci/inspections/inspectionguides/ucm074935.htm.
20. Neutra MR, Kozlowski PA. 2006. Mucosal vaccines: The promise and the challenge. Nat Rev Immunol 6:148-158.
21. Lin IC, Liang M, Liu TY, Monteiro MJ, Toth I. 2012. Cellular transport pathways of polymer coated gold nanoparticles. Nanomed Nanotechnol 8:8-11.
22. Boyaka PN, Marinaro M, Jackson RJ, van Ginkel FW, Boyaka EC, Kirk KL, Kensil CR, McGhee JR. 2001. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J Immunol 166(2001):2283-2290.